Sekunjalo- Acquires 50.6% Of Bioclones

Sekunjalo- Acquires 50.6% Of Bioclones                                          
SEKUNJALO INVESTMENTS LIMITED                                                   
(Incorporated in the Republic of South Africa)                                  
Registration number 1996/006093/06                                              
Share Code: SKJ            ISIN: ZAE000017893                                   
("Sekunjalo")                                                                   
Press Release                                                                   
28 June 2005                                                                    
Sekunjalo Investments is pleased to announce that it has acquired 50,6% of      
Bioclones with the option to increase its shareholding to 60,4%.                
Sekunjalo"s CEO describes the acquisition as an important development in the    
Company"s history that will allow it to become an influential player in the     
global pharmaceutical and biotechnology sector.                                 
Bioclones is a biotechnology company devoted to the development and manufacture 
of biotechnology products for human pharmaceutical use, with new developments   
focussed on the treatment of diseases in man due to failure of cellular immune  
responses.  The biotechnology products are aimed at areas relating to infectious
diseases, cancers and auto-immune diseases.  Bioclones is the largest           
Biotechnology Company in Africa developing modern biotechnology products for    
human pharmaceutical use.                                                       
Dr Donninger, CEO and Shareholder of Bioclones has indicated that the           
partnership with Sekunjalo allows Bioclones to unlock the value in its          
technology and patents which are currently registered worldwide.  Dr Donninger  
has said, that Sekunjalo"s focus and business model of putting people before    
profits, has made this partnership attractive since it will now be possible to  
assist in the development of biotechnology solutions to overcome many of the    
infectious diseases facing Africa today.  Dr Donninger has indicated that       
Bioclones is at the cutting edge of technology and through its scientists is    
able to add significant value to the growth of the biotechnology and            
pharmaceutical sector such that it brings affordable solutions to Africa"s      
population.                                                                     
Dr Surve, CEO of Sekunjalo has said that Bioclones is an opportunity for        
Sekunjalo to combine its significant interest in the health care sector along   
with its corporate expertise to unlock the value present in 22 worldwide        
registered patents and 8 current patents pending for registration worldwide.  Dr
Surve has said that the product portfolio of Biocolones is world class and lends
itself to a potential listing in London and on the Nasdaq.  In this regard, the 
new board of Bioclones and Sekunjalo will jointly be exploring the listing of   
Bioclones on international stock exchanges.  At the appropriate time an         
announcement will be made with regard to the above.                             
Dr Surve has indicated that Sekunjalo"s subsidiary African Biotechnology and    
Medical Innovation Investments will be structured to incorporate all the group"s
biotechnology investments in the enzyme technology sector (medical              
biotechnology), aquaculture (abalone), Plant Biotechnology (Seagro) and Medical 
diagnostics (Uricheck) with a view to consolidating the largest African         
Biotechnology company in support of development solutions for Africa.  Dr Surve 
has mentioned that whilst the greatest beneficiary of these biotechnology       
innovations will be South Africans and Africans, the commercial prospects are   
excellent worldwide especially in North America, Europe and Asia where similar  
biotechnology companies, with similar product portfolio"s have significant      
values.                                                                         
- end -                                                                         
Date: 28/06/2005 04:46:04 PM Supplied by www.sharenet.co.za                     
Produced by the JSE SENS Department